A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution Experience
<span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Aim: To assess the efficacy of reirradiation in locoregionally recurrent head and neck cancer (HNC) and </spa...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine
2016-06-01
|
| Series: | Research in Oncology |
| Subjects: | |
| Online Access: | https://resoncol.journals.ekb.eg/article_587_c9dc1a19a6306d4d48666d1f41703538.pdf |
| Summary: | <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Aim: To assess the efficacy of reirradiation in locoregionally recurrent head and neck cancer (HNC) and </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">to describe results in our center in relation to other published data among similar group of patients. </span></span><br /> <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Methods: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">The medical records of 28 patients with HNC who received reirradiation with or without chemotherapy for loco-regional recurrence between 2005 and 2013 were reviewed. They were evaluated </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">for; toxicity profile, overall survival (OS) and progression free survival (PFS). </span></span></span></span><br /> <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Results: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">The median reirradiation dose was 50 Gy (range 40-60 Gy) and median radiation cumulative dose was 119 (range 113 -120). An overall response rate was seen in 36% of patients with only 3 patients showed complete response. The median OS was 9 months with 1-and 2-year survival rates being 34.1% </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">and 10.6%. The OS and PFS were significantly better in patients who were treated with chemotherapy </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">concomitant with radiation and received higher radiation dose. Grade 3 mucositis and skin reactions were seen in 24 % and 14% of patients, respectively. Conclusion: <span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">Reirradiation appears to be feasible in patients with recurrent HNC treated previously with </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">radiation. The benefit of concurrent chemotherapy with reirradiation is expected. Our results are subject </span></span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">to limitations from the retrospective nature of the analysis, the relatively small number, and improper selection of patients. </span></span></span></span></span></span></span></span> |
|---|---|
| ISSN: | 2357-0687 2357-0695 |